Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Agreement reached with FDA on Phase 2 pivotal study design of RP-L301 for PKD to support accelerated approval; Initiating single-arm, 10-patient pivotal study with primary endpoint of ≥1.5 point Hgb improvement at 12 monthsInitiated Phase 2 pivotal trial of RP-A501 for Danon Disease following FDA alignmentInitiated...

Related Keywords

United Kingdom ,Gaurav Shah ,Kevin Giordano ,Journal Of The American College Cardiology ,International Consensus On Differential Diagnosis ,Rocket Pharmaceuticals Inc ,Nasdaq ,Company Cranbury ,Danon Disease ,Priority Review ,Fanconi Anemia ,Rocket Pharmaceuticals ,Chief Executive Officer ,Differential Diagnosis ,American College ,Clinical Trial Application ,Investigational Medicinal Product Dossier ,Adhesion Deficiency I ,Kinase Deficiency ,Subsequent Malignancy ,Pediatric Blood ,Healthcare Conference ,Annual Evercore ,Leukocyte Adhesion Deficiency I ,Pyruvate Kinase Deficiency ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Months Ended September ,